Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 10/2009

01-10-2009 | Original Article

Activation of tumor-specific T lymphocytes after laser-induced thermotherapy in patients with colorectal liver metastases

Authors: Thomas Josef Vogl, Thaddäus T. Wissniowski, Nagy N. N. Naguib, Renate M. Hammerstingl, Martin G. Mack, Sabine Münch, Matthias Ocker, Deike Strobel, Eckhart G. Hahn, Johannes Hänsler

Published in: Cancer Immunology, Immunotherapy | Issue 10/2009

Login to get access

Abstract

Purpose

To asses if laser-induced thermotherapy (LITT) induces a specific cytotoxic T cell response in patients treated with LITT for colorectal cancer liver metastases.

Methods

Eleven patients with liver metastases of colorectal cancer underwent LITT. Blood was sampled before and after LITT. Peripheral T cell activation was assessed by an interferon gamma (IFNg) secretion assay and flow cytometry. Test antigens were autologous liver and tumor lysate obtained from each patient by biopsy. T cells were stained for CD3/CD4/CD8 and IFNg to detect activated T cells. The ratio of IFNg positive to IFNg negative T cells was determined as the stimulation index (SI). To assess cytolytic activity, T cells were co-incubated with human colorectal cancer cells (CaCo) and cytosolic adenylate kinase release was measured by a luciferase assay.

Results

IFNg secretion assay: before LITT SI was 12.73 (±4.83) for CD3+, 4.36 (±3.32) for CD4+ and 3.64 (±1.77) for CD8+ T cells against autologous tumor tissue. Four weeks after LITT SI had increased to 92.09 (±12.04) for CD3+ (P < 0.001), 42.92 (±16.68) for CD4+ (P < 0.001) and 47.54 (±15.68) for CD8+ T cells (P < 0.001) against autologous tumor tissue. No increased SI was observed with normal liver tissue at any time point. Cytotoxicity assay: before LITT activity against the respective cancer cells was low, with RLU = 1,493 (±1,954.68), whereas after LITT cytolytic activity had increased to RLU = 7,260 [±3,929.76 (P < 0.001)].

Conclusion

Patients with liver metastases of colorectal cancer show a tumor-specific cytotoxic T cell stimulation and a significantly increased cytolytic activity of CD3+, CD4+ and CD8+ T cells after LITT against an allogenic tumor (CaCo cell line).
Literature
1.
go back to reference Jiang HC, Liu LX, Piao DX, Xu J, Zheng M, Zhu AL, Qi SY, Zhang WH, Wu LF (2002) Clinical short-term results of radiofrequency ablation in liver cancers. World J Gastroenterol 8(4):624–630PubMed Jiang HC, Liu LX, Piao DX, Xu J, Zheng M, Zhu AL, Qi SY, Zhang WH, Wu LF (2002) Clinical short-term results of radiofrequency ablation in liver cancers. World J Gastroenterol 8(4):624–630PubMed
2.
go back to reference Vogl TJ, Straub R, Eichler K, Söllner O, Mack MG (2004) Colorectal carcinoma metastases in liver: laser-induced interstitial thermotherapy—local tumor control rate and survival data. Radiology 230:450–458PubMedCrossRef Vogl TJ, Straub R, Eichler K, Söllner O, Mack MG (2004) Colorectal carcinoma metastases in liver: laser-induced interstitial thermotherapy—local tumor control rate and survival data. Radiology 230:450–458PubMedCrossRef
3.
go back to reference Solbiati L, Livraghi T, Goldberg SN, Ierace T, Meloni F, Dellanoce M, Cova L, Halpern EF, Gazelle GS (2001) Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 221(1):159–166PubMedCrossRef Solbiati L, Livraghi T, Goldberg SN, Ierace T, Meloni F, Dellanoce M, Cova L, Halpern EF, Gazelle GS (2001) Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 221(1):159–166PubMedCrossRef
4.
go back to reference Hansler J, Wissniowski TT, Schuppan D, Witte A, Bernatik T, Hahn EG, Strobel D (2006) Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases. World J Gastroenterol 12(23):3716–3721PubMed Hansler J, Wissniowski TT, Schuppan D, Witte A, Bernatik T, Hahn EG, Strobel D (2006) Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases. World J Gastroenterol 12(23):3716–3721PubMed
5.
go back to reference Wissniowski TT, Hansler J, Neureiter D, Frieser M, Schaber S, Esslinger B, Voll R, Strobel D, Hahn EG, Schuppan D (2003) Activation of tumor-specific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits. Cancer Res 63(19):6496–6500PubMed Wissniowski TT, Hansler J, Neureiter D, Frieser M, Schaber S, Esslinger B, Voll R, Strobel D, Hahn EG, Schuppan D (2003) Activation of tumor-specific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits. Cancer Res 63(19):6496–6500PubMed
6.
go back to reference Isbert C, Ritz JP, Roggan A, Schuppan D, Rühl M, Buhr HJ, Germer CT (2004) Enhancement of the immune response to residual intrahepatic tumor tissue by laser-induced thermotherapy (LITT) compared to hepatic resection. Lasers Surg Med 35:284–292PubMedCrossRef Isbert C, Ritz JP, Roggan A, Schuppan D, Rühl M, Buhr HJ, Germer CT (2004) Enhancement of the immune response to residual intrahepatic tumor tissue by laser-induced thermotherapy (LITT) compared to hepatic resection. Lasers Surg Med 35:284–292PubMedCrossRef
7.
go back to reference Ivarsson K, Myllymäki L, Jansner K, Stenram U, Tranberg KG (2005) Resistance to tumour challenge after tumour laser thermotherapy is associated with a cellular immune response. Br J Cancer 93:435–440PubMedCrossRef Ivarsson K, Myllymäki L, Jansner K, Stenram U, Tranberg KG (2005) Resistance to tumour challenge after tumour laser thermotherapy is associated with a cellular immune response. Br J Cancer 93:435–440PubMedCrossRef
8.
go back to reference Frezza EE, Wachtel MS, Barragan B, Chiriva-Internati M, Cobos E (2007) The role of radiofrequency ablation in multiple liver metastases to debulk the tumor: a pilot study before alternative therapies. J Laparoendosc Adv Surg Tech A 17(3):282–284PubMedCrossRef Frezza EE, Wachtel MS, Barragan B, Chiriva-Internati M, Cobos E (2007) The role of radiofrequency ablation in multiple liver metastases to debulk the tumor: a pilot study before alternative therapies. J Laparoendosc Adv Surg Tech A 17(3):282–284PubMedCrossRef
9.
10.
go back to reference Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J, EASL Panel of Experts on HCC (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35(3):421–430PubMedCrossRef Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J, EASL Panel of Experts on HCC (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35(3):421–430PubMedCrossRef
11.
go back to reference Helmberger T, Dogan S, Straub G, Schrader A, Jüngst C, Reiser M, Waggershauser T, Jakobs T, Hoffmann RT, Löhe F, Graeb C, Rau HG, Schauer R, Jauch KW, Caselmann WH, Göke B, Jüngst D (2007) Liver resection or combined chemoembolization and radiofrequency ablation improve survival in patients with hepatocellular carcinoma. Digestion 75(2–3):104–112PubMedCrossRef Helmberger T, Dogan S, Straub G, Schrader A, Jüngst C, Reiser M, Waggershauser T, Jakobs T, Hoffmann RT, Löhe F, Graeb C, Rau HG, Schauer R, Jauch KW, Caselmann WH, Göke B, Jüngst D (2007) Liver resection or combined chemoembolization and radiofrequency ablation improve survival in patients with hepatocellular carcinoma. Digestion 75(2–3):104–112PubMedCrossRef
12.
go back to reference Livraghi T, Goldberg SN, Solbiati L, Meloni F, Ierace T, Gazelle GS (2001) Percutaneous radio-frequency ablation of liver metastases from breast cancer: initial experience in 24 patients. Radiology 220(1):145–149PubMed Livraghi T, Goldberg SN, Solbiati L, Meloni F, Ierace T, Gazelle GS (2001) Percutaneous radio-frequency ablation of liver metastases from breast cancer: initial experience in 24 patients. Radiology 220(1):145–149PubMed
13.
go back to reference Solbiati L, Ierace T, Tonolini M, Osti V, Cova L (2001) Radiofrequency thermal ablation of hepatic metastases. Eur J Ultrasound 13(2):149–158PubMedCrossRef Solbiati L, Ierace T, Tonolini M, Osti V, Cova L (2001) Radiofrequency thermal ablation of hepatic metastases. Eur J Ultrasound 13(2):149–158PubMedCrossRef
14.
go back to reference Gazelle GS, Goldberg SN, Solbiati L, Livraghi T (2000) Tumor ablation with radio-frequency energy. Radiology 217(3):633–646PubMed Gazelle GS, Goldberg SN, Solbiati L, Livraghi T (2000) Tumor ablation with radio-frequency energy. Radiology 217(3):633–646PubMed
15.
go back to reference Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–321PubMedCrossRef Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–321PubMedCrossRef
16.
go back to reference Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ, Cameron JL (2002) Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235:759–766PubMedCrossRef Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ, Cameron JL (2002) Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235:759–766PubMedCrossRef
17.
go back to reference Mutsaerts EL, van Ruth S, Zoetmulder FA, Rutgers EJ, Hart AA, van Coevorden F (2005) Prognostic factors and evaluation of surgical management of hepatic metastases from colorectal origin: a 10-year single-institute experience. J Gastrointest Surg 9:178–186PubMedCrossRef Mutsaerts EL, van Ruth S, Zoetmulder FA, Rutgers EJ, Hart AA, van Coevorden F (2005) Prognostic factors and evaluation of surgical management of hepatic metastases from colorectal origin: a 10-year single-institute experience. J Gastrointest Surg 9:178–186PubMedCrossRef
18.
go back to reference Masters A, Steger AC, Lees WR, Walmsley KM, Bown SG (1992) Interstitial laser hyperthermia: a new approach for treating liver metastases. Br J Cancer 66:518–522PubMed Masters A, Steger AC, Lees WR, Walmsley KM, Bown SG (1992) Interstitial laser hyperthermia: a new approach for treating liver metastases. Br J Cancer 66:518–522PubMed
19.
go back to reference Nolsoe CP, Torp-Pedersen S, Burcharth F, Horn T, Pedersen S, Christensen NE, Olldag ES, Andersen PH, Karstrup S, Lorentzen T (1993) Interstitial hyperthermia of colorectal liver metastases with a US-guided Nd-YAG laser with a diffuser tip: a pilot clinical study. Radiology 187:333–337PubMed Nolsoe CP, Torp-Pedersen S, Burcharth F, Horn T, Pedersen S, Christensen NE, Olldag ES, Andersen PH, Karstrup S, Lorentzen T (1993) Interstitial hyperthermia of colorectal liver metastases with a US-guided Nd-YAG laser with a diffuser tip: a pilot clinical study. Radiology 187:333–337PubMed
20.
go back to reference Schroder T, Castren-Persons M, Lehtinen A, Taavitsainen M (1994) Percutaneous interstitial laser hyperthermia in clinical use. Ann Chir Gynaecol 83:286–290PubMed Schroder T, Castren-Persons M, Lehtinen A, Taavitsainen M (1994) Percutaneous interstitial laser hyperthermia in clinical use. Ann Chir Gynaecol 83:286–290PubMed
21.
go back to reference Muralidharan V, Christophi C (2001) Interstitial laser thermotherapy in the treatment of colorectal liver metastases. J Surg Oncol 76:73–81PubMedCrossRef Muralidharan V, Christophi C (2001) Interstitial laser thermotherapy in the treatment of colorectal liver metastases. J Surg Oncol 76:73–81PubMedCrossRef
22.
go back to reference Jacques SL (1992) Laser–tissue interactions. Photochemical, photothermal, and photomechanical. Surg Clin North Am 72(3):531–558 (review)PubMed Jacques SL (1992) Laser–tissue interactions. Photochemical, photothermal, and photomechanical. Surg Clin North Am 72(3):531–558 (review)PubMed
23.
go back to reference Zerbini A, Pilli M, Penna A, Orlandini A, Mezzadri S, Sacchelli L, Missale G, Ferrari C (2006) Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res 66(2):1139–1146PubMedCrossRef Zerbini A, Pilli M, Penna A, Orlandini A, Mezzadri S, Sacchelli L, Missale G, Ferrari C (2006) Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res 66(2):1139–1146PubMedCrossRef
24.
go back to reference den Brok MH, Sutmuller RP, van der Voort R, Bennink EJ, Figdor CG, Ruers TJ, Adema GJ (2004) In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res 64(11):4024–4029CrossRef den Brok MH, Sutmuller RP, van der Voort R, Bennink EJ, Figdor CG, Ruers TJ, Adema GJ (2004) In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res 64(11):4024–4029CrossRef
Metadata
Title
Activation of tumor-specific T lymphocytes after laser-induced thermotherapy in patients with colorectal liver metastases
Authors
Thomas Josef Vogl
Thaddäus T. Wissniowski
Nagy N. N. Naguib
Renate M. Hammerstingl
Martin G. Mack
Sabine Münch
Matthias Ocker
Deike Strobel
Eckhart G. Hahn
Johannes Hänsler
Publication date
01-10-2009
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 10/2009
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-009-0663-1

Other articles of this Issue 10/2009

Cancer Immunology, Immunotherapy 10/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine